TD Cowen has initiated coverage on Mirum Pharmaceuticals Inc (MIRM) with a Buy rating, marking the firm's first assessment of the company's investment potential. This decision reflects an analysis of Mirum's business model, industry dynamics, and growth prospects in the biotechnology sector.
Headquartered in Foster City, California, Mirum Pharmaceuticals is focused on developing treatments for rare diseases affecting both children and adults. The company currently markets three medicines: LIVMARLI (maralixibat) oral solution, Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. LIVMARLI is specifically used to treat cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis. As of November 20, 2025, Mirum has a market capitalization of $3.6 billion and an earnings per share (EPS) of -0.87.
Looking ahead, Mirum is set to report its upcoming earnings on August 4, 2026, with an estimated EPS of $0.04 and projected revenue of $150.8 million. Recent earnings performance has shown significant surprises, including a Q3 2025 EPS of $0.05, exceeding estimates by 129.8%.
Analyst ratings serve as professional opinions based on extensive research and financial modeling. While they can offer valuable insights, these assessments are based on assumptions that may not always hold true. Therefore, investment decisions should encompass a range of factors, including company fundamentals and industry trends. It's also important to note that analyst ratings can evolve as new information emerges, reflecting the dynamic nature of financial markets.